Evidence map›Paper›PMID 41995421›Full record

Trial reportJournal of Parkinson's disease2026

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.

Joaquim J Ferreira, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Joana Moreira, Miguel M Fonseca, José-Francisco Rocha, Helena C Brigas, Joerg Holenz, Werner Poewe and 1 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04978597 (A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04978597 phase3completednot on this map

A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson's Disease Patients, With an Open-Label Extension

TypeinterventionalSponsorBial - Portela C S.A.Ran2021 to 2024Enrolled410ConditionsParkinsonArmsOpicapone 50 mg, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joaquim J FerreiraLaboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade Lisboa, Lisbon, Portugal.
Olivier RascolClinical Investigation Centre CIC1436 Departments of Neurosciences and Clinical Pharmacology, Centre of Excellence for Neurodegeneration COEN NeuroToul, and NS-Park/FCRIN network; University of Toulouse 3, University Hospital of Toulouse, INSERM, Toulouse, France.
Fabrizio StocchiDepartment of Neurology, Institute for Research and Medical Care IRCCS San Raffaele, Roma, Italy.
Angelo AntoniniNeurodegenerative Disease Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padova, Padova, Italy.
Joana MoreiraBIAL - Portela & Ca S.A., Coronado, Portugal.
Miguel M FonsecaBIAL - R&D INVESTMENTS, S.A, Porto, Portugal.
José-Francisco RochaBIAL - Portela & Ca S.A., Coronado, Portugal.
Helena C BrigasBIAL - Portela & Ca S.A., Coronado, Portugal.
Joerg HolenzBIAL - Portela & Ca S.A., Coronado, Portugal.
Werner PoeweDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Epsilon Study investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary results from the 24-week EPSILON study (NCT04978597) showed that adding opicapone to levodopa in non-fluctuating Parkinson's patients significantly improved motor impairment without increasing the development of motor complications versus placebo. All participants finishing the double-blind phase became eligible for open-label treatment with opicapone. Symptomatic efficacy of opicapone was maintained with 1-year open-label treatment (adjusted-mean ± SE change in MDS-UPDRS motor score from double-blind baseline to Week 76: -7.4 ± 0.81); participants who switched from placebo to opicapone had a motor improvement of -6.1 ± 0.79. At Week 76, 80.2% of opicapone-opicapone-treated participants remained motor complication-free versus 69.7% in the placebo-opicapone group (p = 0.1).

Indexed as

Antiparkinson AgentsLevodopaOxadiazolesParkinson DiseaseAgedDouble-Blind MethodDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMiddle AgedAntiparkinson AgentsLevodopaopicaponeOxadiazolesclinical trialCOMTlevodopaopicaponeParkinson's disease

Identifiers

PMID41995421
PMCPMC13437903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.